A phase II combination trial of lonafarnib, ritonavir and pegylated interferon lambda in hepatitis delta virus infected patients
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Lonafarnib (Primary) ; Peginterferon lambda-1a (Primary) ; Ritonavir (Primary)
- Indications Hepatitis D
- Focus Therapeutic Use
- Acronyms LIFT
- 21 Mar 2018 According to Eiger BioPharmaceuticals media release, will be conducted within the National Institutes of Health (NIH) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and enrollment is planned for 2Q 2018.
- 02 Sep 2016 New trial record
- 10 Aug 2016 According to Eiger BioPharmaceuticals media release, this trial is likely to begin in 2017.